EU says 'no evidence' to restrict use of AstraZeneca vaccine
The European Medicines Agency says there is “no evidence” that would support restricting use of AstraZeneca’s coronavirus vaccine in any population despite reports of rare blood clots associated with the shot
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The head of the European Medicines Agency said Wednesday that there is “no evidence” that would support restricting use of AstraZeneca’s coronavirus vaccine in any population, as Germany has now done amid concerns over rare blood clots in people who got the shot.
But EMA Executive Director Emer Cooke said her agency continues to study reports of new cases as they come in and will provide a further assessment next week.
On Tuesday, an independent vaccine expert panel in Germany said the AstraZeneca shot should not routinely be given to people under 60 because of a rise in reported cases of unusual blood clots in the days after vaccination. The German government followed the recommendation and said the shot will now be prioritized for people age 60 and older.
“According to the current scientific knowledge, there is no evidence that would support restricting the use of this vaccine in any population," Cooke told reporters.
She said the assessment was based on 62 cases of unusual blood clots, including 14 deaths, reported to EMA by March 22. Those figures included a “significant” number of the cases reported from Germany, but not all, she said.
German regulators said they received 31 reports of so-called sinus vein thrombosis in recipients of the AstraZeneca vaccine and nine deaths up to March 29.